661: Obstetric hemorrhage management among obese women
نویسندگان
چکیده
منابع مشابه
Management of obstetric hemorrhage.
Major obstetric hemorrhage is an extremely challenging obstetric emergency associated with significant morbidity and mortality. Pharmacological treatment of uterine atony has not altered much in recent years apart from the increasing use ofmisoprostol, although controversy surrounds its advantages over other uterotonics. Placenta accreta is becoming more common, a sequel to the rising caesarean...
متن کاملTransfusion Management of Obstetric Hemorrhage
‘. . . if you have under care a patient in whom the flooding has been copious, in whom, further, the womb has been emptied, and the haemorrhages been stopped; should this woman, as I have myself on several occasions seen, be sinking gradually into the grave, so that even to those who have seen much of floodings the case appears to be without hope: under such circumstances, I affirm that it is h...
متن کاملIdentification and Management of Obstetric Hemorrhage.
Obstetric hemorrhage remains the leading cause of maternal death and severe morbidity worldwide. Although uterine atony is the most common cause of peripartum bleeding, abnormal placentation, coagulation disorders, and genital tract trauma contribute to adverse maternal outcomes. Given the inability to reliably predict patients at high risk for obstetric hemorrhage, all parturients should be co...
متن کاملThe role of the anesthesiologist in management of obstetric hemorrhage.
Hemorrhage after childbirth, whether the delivery is vaginal or operative, is a clinical situation where knowledge, communication, and the availability and utilization of resources all play prominent roles. In this article we describe the thought processes and decisions that should occur, and the actions that should be taken by the anesthesiologist in the face of suspected, expected, or unexpec...
متن کاملA Retrospective Analysis of Transfusion Management for Obstetric Hemorrhage in a Japanese Obstetric Center
Background. Since cryoprecipitate, fibrinogen concentrate, or recombinant activated factor VII is not approved by public medical insurance in Japan, we retrospectively assessed blood product usage in patients with obstetric hemorrhage at our tertiary obstetric center. Material and Methods. 220 patients with obstetric hemorrhagic disorders who underwent blood product transfusion in our instituti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Obstetrics and Gynecology
سال: 2019
ISSN: 0002-9378
DOI: 10.1016/j.ajog.2018.11.683